Overview

A Study of Children With Refractory or Relapsed ALL

Status:
Completed
Trial end date:
2003-12-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to find out which form of asparaginase (the native E. coli/Erwinia) or PEG-asparaginase) is more effective during induction treatment for children with acute lymphoblastic leukemia that has come back after treatment (relapsed) or is resistant to treatment (refractory)
Phase:
Phase 3
Details
Lead Sponsor:
St. Jude Children's Research Hospital
Treatments:
6-Mercaptopurine
Asparaginase
Dexamethasone
Etoposide
Fludarabine
Idarubicin
Mercaptopurine
Methotrexate
Pegaspargase
Teniposide
Topotecan
Vincristine